Gut Microbiota Has the Potential to Improve Sarcopenic Obesity in Menopausal Women by Regulating Estrogen.

Researchers have explored how gut bacteria might help address a common problem in menopausal women: losing muscle while gaining belly fat, a condition called sarcopenic obesity. When estrogen levels drop during menopause, it doesn't just cause hot flashes—it can trigger muscle loss and weight gain around the middle. This study reviewed evidence showing that gut bacteria play an important role in recycling estrogen in the body and may influence both muscle and fat tissue health.

The researchers found that after menopause, certain beneficial gut bacteria decrease, which reduces the body's ability to recycle estrogen through the digestive system. This imbalance can trigger inflammation that breaks down muscle while promoting fat storage. Some gut bacteria produce short-chain fatty acids that help regulate blood sugar and may protect against these changes. Studies also showed that postmenopausal women have less diverse gut bacteria and higher inflammation levels.

Some small trials combining soy isoflavones (plant estrogens) with probiotics showed improvements in cholesterol levels, though effects on muscle haven't been well studied yet. The authors emphasize that while this research is promising, most evidence comes from animal studies and small human trials. Larger clinical studies are needed before gut-focused treatments can be recommended.

For women experiencing menopausal symptoms and body composition changes, acupuncture may offer complementary support by addressing hormonal balance, reducing inflammation, and supporting metabolic health through its effects on the nervous and endocrine systems. If you're interested in exploring acupuncture for menopausal concerns, seek care from a board-certified or licensed acupuncturist with experience in women's health.

This systematic review examines the gut microbiota-estrogen-sarcopenic obesity axis in menopausal women. Key mechanisms identified include menopause-related reduction in microbial β-glucuronidase activity, impairing enterohepatic estrogen recirculation, and dysbiosis-induced LPS-TLR4 pathway activation promoting muscle catabolism via MuRF1 upregulation and adipogenic inflammation. Short-chain fatty acid production enhances insulin sensitivity through GLP-1 stimulation. Population studies demonstrate reduced microbiota diversity and altered Firmicutes/Bacteroidetes ratios correlating with systemic inflammation and metabolic dysfunction in postmenopausal women. Limited intervention data from combined soy isoflavone-probiotic trials show lipid improvements without muscle outcome assessment. The review synthesizes animal models, mechanistic studies, and small human trials but lacks specific sample sizes or effect sizes. Clinical implications suggest the microbiota-estrogen axis represents a potential therapeutic target, though current evidence remains primarily preclinical. Authors emphasize need for rigorous large-scale RCTs before recommending microbiota-based interventions as adjunctive therapy for menopausal sarcopenic obesity.